Baxter International Inc. (BAX)
NYSE: BAX · Real-Time Price · USD
24.25
+0.14 (0.58%)
Aug 14, 2025, 12:02 PM - Market open
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| Chronic Therapies | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Chronic Therapies Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medication Delivery | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medication Delivery Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Clinical Nutrition | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Clinical Nutrition Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Advanced Surgery | 1.10B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Advanced Surgery Growth | 5.13% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceuticals | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceuticals Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Acute Therapies | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Acute Therapies Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Patient Support Systems | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Patient Support Systems Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Surgical Solutions | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Surgical Solutions Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Front Line Care | 1.14B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Front Line Care Growth | -1.63% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Injectables and Anesthesia | 1.37B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Injectables and Anesthesia Growth | -0.58% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Drug Compounding | 1.04B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Drug Compounding Growth | 7.78% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Revenue (Post-Q2 2023 Reporting) | 67.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Revenue (Post-Q2 2023 Reporting) Growth | 198.63% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Infusion Therapies | 4.10B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Infusion Therapies Growth | 1.33% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Care & Connectivity Solutions | 1.81B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Care & Connectivity Solutions Growth | 4.02% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| BioPharma Solutions | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| BioPharma Solutions Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Revenue (Pre-Q3 2023 Reporting) | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Revenue (Pre-Q3 2023 Reporting) Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| Other | -861.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | -30.01% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medical Products & Therapies Operating Income | 950.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Medical Products & Therapies Operating Income Growth | -0.82% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Healthcare Systems & Technologies Operating Income | 468.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Healthcare Systems & Technologies Operating Income Growth | 7.42% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceuticals Operating Income | 313.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceuticals Operating Income Growth | -24.07% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Kidney Care Operating Income | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Operating Income | 18.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Operating Income Growth | 11.11% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | -861.00M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Growth | -30.01% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2012 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2012 - 2019 |
| United States | 5.85B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| United States Growth | 3.91% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Emerging Markets | 1.35B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Emerging Markets Growth | -2.05% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of World | 3.44B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rest of World Growth | 5.37% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Americas | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Americas Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| EMEA | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| EMEA Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| APAC | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| APAC Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Hillrom | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Hillrom Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2011 - 2018 |
|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2011 - 2018 |
| Americas Operating Income |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Americas Operating Income Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| EMEA Operating Income |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| EMEA Operating Income Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| APAC Operating Income |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| APAC Operating Income Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Hillrom Operating Income |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Hillrom Operating Income Growth |
Log In |
Log In |
Log In |
Log In | Upgrade
|